Modality

Modality.AI develops a conversational artificial intelligence platform designed for the objective and precise assessment of neurological and psychiatric conditions within clinical research. The platform utilizes multimodal analysis, interpreting speech, facial expressions, and motor functions captured during structured conversations with a virtual assistant named Tina. This technology delivers standardized, remote, and real-time data, aiming to enhance the accuracy and efficiency of clinical trials.

The company was established in 2018 by co-founders David Suendermann-Oeft, PhD, and David Pautler, PhD. Both are recognized experts in artificial intelligence and signal processing, bringing a deep technical understanding to the venture. Their foundational insight was the critical need for a more objective and scalable method to quantify subtle changes in patient conditions, moving beyond the inherent subjectivity of traditional rater-based evaluations in neurological and psychiatric studies.

Pharma and biotech sponsors constitute the primary user base for Modality.AI’s platform, leveraging it to supplement or replace conventional assessments in regulated clinical trials. The product enables rigorous data collection in diverse settings, from in-clinic to fully decentralized studies, across multiple languages. Modality.AI envisions transforming the landscape of clinical research by providing reliable, science-first digital measures that accelerate insights into disease progression and treatment response.